WO2013015661A2 - Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide - Google Patents
Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide Download PDFInfo
- Publication number
- WO2013015661A2 WO2013015661A2 PCT/KR2012/006043 KR2012006043W WO2013015661A2 WO 2013015661 A2 WO2013015661 A2 WO 2013015661A2 KR 2012006043 W KR2012006043 W KR 2012006043W WO 2013015661 A2 WO2013015661 A2 WO 2013015661A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- oxadiazol
- methyl
- ethylcarbamoyl
- Prior art date
Links
- 229940002612 prodrug Drugs 0.000 title claims abstract description 17
- 239000000651 prodrug Substances 0.000 title claims abstract description 17
- LKYNGTHMKCTTQC-UHFFFAOYSA-N 1,2-oxazole-3-carboxamide Chemical compound NC(=O)C=1C=CON=1 LKYNGTHMKCTTQC-UHFFFAOYSA-N 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 113
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims abstract description 34
- -1 2-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl dihydrogen phosphate Chemical compound 0.000 claims description 33
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 5
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 5
- 239000000920 calcium hydroxide Substances 0.000 claims description 5
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 5
- LRAADRPPWVSTOF-UHFFFAOYSA-L dipotassium [2-[3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)-1,2-oxazol-5-yl]-5-hydroxy-4-propan-2-ylphenyl] phosphate Chemical compound [K+].[K+].CCNC(=O)c1noc(c1-c1noc(C)n1)-c1cc(C(C)C)c(O)cc1OP([O-])([O-])=O LRAADRPPWVSTOF-UHFFFAOYSA-L 0.000 claims description 5
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 5
- 239000000347 magnesium hydroxide Substances 0.000 claims description 5
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- AZVDNHQUPDKCEO-UHFFFAOYSA-N [2-[3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)-1,2-oxazol-5-yl]-5-phosphonooxy-4-propan-2-ylphenyl] dihydrogen phosphate Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OP(O)(O)=O)=C(C(C)C)C=2)OP(O)(O)=O)=C1C1=NOC(C)=N1 AZVDNHQUPDKCEO-UHFFFAOYSA-N 0.000 claims description 4
- SHMDGALAMSNXRJ-UHFFFAOYSA-L [K+].[K+].CCNC(=O)C1=NOC(C=2C=3OP(=O)(OP([O-])([O-])=O)OC(C=3)=C(C(C)C)C=2)=C1C1=NOC(C)=N1 Chemical compound [K+].[K+].CCNC(=O)C1=NOC(C=2C=3OP(=O)(OP([O-])([O-])=O)OC(C=3)=C(C(C)C)C=2)=C1C1=NOC(C)=N1 SHMDGALAMSNXRJ-UHFFFAOYSA-L 0.000 claims description 4
- MYHJLQOCYYFNLG-UHFFFAOYSA-L [Na+].[Na+].CCNC(=O)C1=NOC(C=2C=3OP(=O)(OP([O-])([O-])=O)OC(C=3)=C(C(C)C)C=2)=C1C1=NOC(C)=N1 Chemical compound [Na+].[Na+].CCNC(=O)C1=NOC(C=2C=3OP(=O)(OP([O-])([O-])=O)OC(C=3)=C(C(C)C)C=2)=C1C1=NOC(C)=N1 MYHJLQOCYYFNLG-UHFFFAOYSA-L 0.000 claims description 4
- GWWWNAKRFFANNF-UHFFFAOYSA-N bis(dimethylamino)phosphinic acid Chemical compound CN(C)P(O)(=O)N(C)C GWWWNAKRFFANNF-UHFFFAOYSA-N 0.000 claims description 4
- IDGLVVJBDHUPBX-UHFFFAOYSA-L calcium [2-[3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)-1,2-oxazol-5-yl]-5-hydroxy-4-propan-2-ylphenyl] phosphate Chemical compound [Ca++].CCNC(=O)c1noc(c1-c1noc(C)n1)-c1cc(C(C)C)c(O)cc1OP([O-])([O-])=O IDGLVVJBDHUPBX-UHFFFAOYSA-L 0.000 claims description 4
- FHQHXWZTJYRTHE-UHFFFAOYSA-L calcium [4-[3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)-1,2-oxazol-5-yl]-5-hydroxy-2-propan-2-ylphenyl] phosphate Chemical compound [Ca++].CCNC(=O)c1noc(c1-c1noc(C)n1)-c1cc(C(C)C)c(OP([O-])([O-])=O)cc1O FHQHXWZTJYRTHE-UHFFFAOYSA-L 0.000 claims description 4
- ZMRIQTAEQJLOAV-UHFFFAOYSA-L calcium [6-[3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)-1,2-oxazol-5-yl]-3-oxo-8-propan-2-yl-2,4-dioxa-3lambda5-phosphabicyclo[3.3.1]nona-1(8),5(9),6-trien-3-yl] phosphate Chemical compound [Ca+2].CCNC(=O)C1=NOC(C=2C=3OP(=O)(OP([O-])([O-])=O)OC(C=3)=C(C(C)C)C=2)=C1C1=NOC(C)=N1 ZMRIQTAEQJLOAV-UHFFFAOYSA-L 0.000 claims description 4
- SHFQJFSKRMZGMU-UHFFFAOYSA-L disodium [4-[3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)-1,2-oxazol-5-yl]-5-hydroxy-2-propan-2-ylphenyl] phosphate Chemical compound [Na+].[Na+].CCNC(=O)c1noc(c1-c1noc(C)n1)-c1cc(C(C)C)c(OP([O-])([O-])=O)cc1O SHFQJFSKRMZGMU-UHFFFAOYSA-L 0.000 claims description 4
- UJFLVGBOIDXLMP-UHFFFAOYSA-L magnesium [2-[3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)-1,2-oxazol-5-yl]-5-hydroxy-4-propan-2-ylphenyl] phosphate Chemical compound [Mg++].CCNC(=O)c1noc(c1-c1noc(C)n1)-c1cc(C(C)C)c(O)cc1OP([O-])([O-])=O UJFLVGBOIDXLMP-UHFFFAOYSA-L 0.000 claims description 4
- LOVNZEATULNORV-UHFFFAOYSA-L magnesium [4-[3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)-1,2-oxazol-5-yl]-5-hydroxy-2-propan-2-ylphenyl] phosphate Chemical compound [Mg++].CCNC(=O)c1noc(c1-c1noc(C)n1)-c1cc(C(C)C)c(OP([O-])([O-])=O)cc1O LOVNZEATULNORV-UHFFFAOYSA-L 0.000 claims description 4
- ADRJRBUJJCIRTF-UHFFFAOYSA-L magnesium [6-[3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)-1,2-oxazol-5-yl]-3-oxo-8-propan-2-yl-2,4-dioxa-3lambda5-phosphabicyclo[3.3.1]nona-1(8),5(9),6-trien-3-yl] phosphate Chemical compound [Mg+2].CCNC(=O)C1=NOC(C=2C=3OP(=O)(OP([O-])([O-])=O)OC(C=3)=C(C(C)C)C=2)=C1C1=NOC(C)=N1 ADRJRBUJJCIRTF-UHFFFAOYSA-L 0.000 claims description 4
- WYLQARGYFXBZMD-UHFFFAOYSA-N n-[chloro(dimethylamino)phosphoryl]-n-methylmethanamine Chemical compound CN(C)P(Cl)(=O)N(C)C WYLQARGYFXBZMD-UHFFFAOYSA-N 0.000 claims description 4
- 230000002194 synthesizing effect Effects 0.000 claims description 4
- FBVSXKMMQOZUNU-NSHDSACASA-N N2,N6-Bis{[(2-methyl-2-propanyl)oxy]carbonyl}lysine Chemical compound CC(C)(C)OC(=O)NCCCC[C@@H](C(O)=O)NC(=O)OC(C)(C)C FBVSXKMMQOZUNU-NSHDSACASA-N 0.000 claims description 3
- LPVKENZMCUWOFU-SQKCAUCHSA-N [2-[3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)-1,2-oxazol-5-yl]-5-hydroxy-4-propan-2-ylphenyl] (2S)-2,6-diaminohexanoate dihydrochloride Chemical compound Cl.Cl.CCNC(=O)c1noc(c1-c1noc(C)n1)-c1cc(C(C)C)c(O)cc1OC(=O)[C@@H](N)CCCCN LPVKENZMCUWOFU-SQKCAUCHSA-N 0.000 claims description 3
- RAVIUBFEDFWYAV-UHFFFAOYSA-L dipotassium [4-[3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)-1,2-oxazol-5-yl]-5-hydroxy-2-propan-2-ylphenyl] phosphate Chemical compound [K+].[K+].CCNC(=O)c1noc(c1-c1noc(C)n1)-c1cc(C(C)C)c(OP([O-])([O-])=O)cc1O RAVIUBFEDFWYAV-UHFFFAOYSA-L 0.000 claims description 3
- LEGYPMSJDWOPTC-UHFFFAOYSA-L disodium [2-[3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)-1,2-oxazol-5-yl]-5-hydroxy-4-propan-2-ylphenyl] phosphate Chemical compound [Na+].[Na+].CCNC(=O)c1noc(c1-c1noc(C)n1)-c1cc(C(C)C)c(O)cc1OP([O-])([O-])=O LEGYPMSJDWOPTC-UHFFFAOYSA-L 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 238000010511 deprotection reaction Methods 0.000 claims description 2
- 230000032050 esterification Effects 0.000 claims description 2
- 238000005886 esterification reaction Methods 0.000 claims description 2
- 150000007529 inorganic bases Chemical class 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- WUEPMEXUMQVEGN-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;2,2,2-trifluoro-n-[2-[2-[(2,2,2-trifluoroacetyl)amino]ethylamino]ethyl]acetamide Chemical compound OC(=O)C(F)(F)F.FC(F)(F)C(=O)NCCNCCNC(=O)C(F)(F)F WUEPMEXUMQVEGN-UHFFFAOYSA-N 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 101710113864 Heat shock protein 90 Proteins 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 12
- 230000005764 inhibitory process Effects 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 230000000144 pharmacologic effect Effects 0.000 abstract description 4
- 206010033128 Ovarian cancer Diseases 0.000 abstract description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract description 2
- 206010017758 gastric cancer Diseases 0.000 abstract description 2
- 230000002611 ovarian Effects 0.000 abstract description 2
- 201000011549 stomach cancer Diseases 0.000 abstract description 2
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 239000011541 reaction mixture Substances 0.000 description 24
- 229910001868 water Inorganic materials 0.000 description 23
- 238000005160 1H NMR spectroscopy Methods 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- 239000003814 drug Substances 0.000 description 16
- 229940079593 drug Drugs 0.000 description 15
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
- 230000006837 decompression Effects 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 9
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 8
- DPQHQVWUCNXFTJ-UHFFFAOYSA-N 5-(2,4-dihydroxy-5-propan-2-ylphenyl)-N-ethyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C1=NOC(C)=N1 DPQHQVWUCNXFTJ-UHFFFAOYSA-N 0.000 description 7
- 108010006519 Molecular Chaperones Proteins 0.000 description 7
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 6
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 102000005431 Molecular Chaperones Human genes 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 239000012267 brine Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 3
- 108091006112 ATPases Proteins 0.000 description 3
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 2
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 2
- RBFANGLJEQLSBP-UMSFTDKQSA-N CCNC(C1=NOC(C(C=C2C(C)C)=C([C@@](CCCCNC(OC(C)(C)C)=O)(C(O)=O)NC(OC(C)(C)C)=O)C=C2O)=C1C1=NOC(C)=N1)=O Chemical compound CCNC(C1=NOC(C(C=C2C(C)C)=C([C@@](CCCCNC(OC(C)(C)C)=O)(C(O)=O)NC(OC(C)(C)C)=O)C=C2O)=C1C1=NOC(C)=N1)=O RBFANGLJEQLSBP-UMSFTDKQSA-N 0.000 description 2
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 2
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 2
- 102100039328 Endoplasmin Human genes 0.000 description 2
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 2
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 2
- 102100026973 Heat shock protein 75 kDa, mitochondrial Human genes 0.000 description 2
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 2
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 108010002687 Survivin Proteins 0.000 description 2
- 101150040313 Wee1 gene Proteins 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- FCYRSDMGOLYDHL-UHFFFAOYSA-N chloromethoxyethane Chemical compound CCOCCl FCYRSDMGOLYDHL-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 description 2
- 108010017007 glucose-regulated proteins Proteins 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 150000008299 phosphorodiamidates Chemical class 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 150000005207 1,3-dihydroxybenzenes Chemical class 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 150000008626 4-imidazolidinones Chemical class 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 0 CC(C)c(c(O)c1)cc(-c([o]nc2*)c2-c2n[o]c(C)n2)c1O Chemical compound CC(C)c(c(O)c1)cc(-c([o]nc2*)c2-c2n[o]c(C)n2)c1O 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010045100 HSP27 Heat-Shock Proteins Proteins 0.000 description 1
- 102100039165 Heat shock protein beta-1 Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- MCAHMSDENAOJFZ-UHFFFAOYSA-N Herbimycin A Natural products N1C(=O)C(C)=CC=CC(OC)C(OC(N)=O)C(C)=CC(C)C(OC)C(OC)CC(C)C(OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-UHFFFAOYSA-N 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101000763352 Homo sapiens Heat shock protein 75 kDa, mitochondrial Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 101710204707 Transforming growth factor-beta receptor-associated protein 1 Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 229940125648 antineoplastic drug candidate Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000035567 cellular accumulation Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000006355 external stress Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- MCAHMSDENAOJFZ-BVXDHVRPSA-N herbimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](OC)[C@@H](OC)C[C@H](C)[C@@H](OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-BVXDHVRPSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002990 hypoglossal effect Effects 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 150000002545 isoxazoles Chemical class 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 description 1
- 229960002950 novobiocin Drugs 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- AECPBJMOGBFQDN-YMYQVXQQSA-N radicicol Chemical compound C1CCCC(=O)C[C@H]2[C@H](Cl)C(=O)CC(=O)[C@H]2C(=O)O[C@H](C)C[C@H]2O[C@@H]21 AECPBJMOGBFQDN-YMYQVXQQSA-N 0.000 description 1
- 229930192524 radicicol Natural products 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- ATEBXHFBFRCZMA-VXTBVIBXSA-N rifabutin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 description 1
- 229960000885 rifabutin Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000008864 scrapie Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229950007866 tanespimycin Drugs 0.000 description 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Definitions
- This present invention relates to the compound of Formula I.
- both R 1 and R 2 are PO(OH) 2 or , or wherein R 1 or R 2 is hydrogen and the other R 1 or R 2 is , PO(OH) 2 or , wherein M is Na + , K + , Mg 2+ , or Ca 2+ , and n is 1 or 2, wherein n is 1 and M is Mg 2+ or Ca 2+ , or wherein n is 2 and M is Na + or K + .
- the compound of Formula I may be as a prodrug of the compound of Formula II, 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide, which is HSP90 inhibitory activity, is stated in the following patent, WO 2011/102660.
- a prodrug is in most cases a pharmacologically inactive derivative of a parent drug molecule that requires spontaneous or enzymatic transformation within the body in order to release the active drug, and that has improved delivery properties over the parent drug molecule. It has been shown that a molecule with optimal structural configuration and physicochemical properties for eliciting the desired therapeutic response at its target site does not necessarily possess the best molecular from and properties for its delivery to its point of ultimate action. Usually, only a minor fraction of doses administered reaches the target area and since most agents interact with non-target sites as well, an inefficient delivery may result in undesirable side effects.
- prodrug formation is a means by which a substantial improvement in the overall efficacy of drugs can often be achieved.
- Prodrugs are designed to overcome pharmaceutically and/or pharmacokinetically based problems associated with the parent drug molecule.
- esters as a prodrug type for drugs containing carboxyl or hydroxyl functional group is most popular.
- prodrug derivatives of peptides, 4-imidazolidinones and the like described in Drugs of the Future , 1991, 16(5), 443-458 or N-oxides, described for example in US 5.691.336.
- molecular chaperones are a general term for proteins that form a complex temporally with client proteins to promote the formation of the conformation of the client proteins. These proteins, the activity of which is to help folding and association of protein and to prevent aggregation are broadly defined as molecular chaperones.
- HSPs heat shock proteins
- HSPs and in particular HSP90, are also involved in the regulation of various major functions of the tumor cell, via their association with various client proteins involved in cell proliferation or apoptosis. In these pathologies, approaches aimed at breaking up or at disturbing the function of chaperones could be available for treatment of disease.
- HSP90 chaperons has recently been demonstrated as a particularly promising target in anticancer therapy ([Moloney A. and Workman P., Expert Opin. Biol. Ther. (2002), 2(1), 3-24]; [Choisis et al, Drug Discovery Today (2004), 9, 881-888]).
- HSP90 Heat Shock Protein 90 family proteins included HSP90 ⁇ HSP90 ⁇ GRP94 and HSP75/TRAP1. These proteins represent approximately 1-2% of the total cellular protein mass. It is usually in the form of a dimer in the cell and is associated with multiplicity of proteins, so-called co-chaperones. HSP90 plays a key role in the response to cellular stress by interaction with many proteins whose native folding has been modified by external stress, such as, for example, heat shock, in order to restore the original folding or to prevent aggregation of the proteins ([Smith D.F. et al., Pharmacological Rev. (1998), 50, 493-513]).
- HSP90 is of importance as buffer against the effects of mutations, presumably through correction of incorrect protein folding caused by the mutation ([Rutherford and Lindquist, 1998]). HSP90 also has a regulatory importance. Under physiological conditions, HSP90, together with its homologue in the endoplasmatic reticulum, GRP94, plays a role in the cell balance for ensuring the stability of the conformation and maturing of various client key proteins, such as, EGFR R/HER2, Src, Akt, Raf, MEK, Bcr-Abl, Flt-3, mutated p53, Akt, survivin, Cdk4, Plk, Wee1, VEGF-R, FAK, HIF-1, hTert and c-Met, etc.
- client key proteins such as, EGFR R/HER2, Src, Akt, Raf, MEK, Bcr-Abl, Flt-3, mutated p53, Akt, survivin, Cdk4, Plk, Wee1,
- client proteins are involved in the six mechanisms of tumour progression. i) An ability to proliferate in the absence of growth factor(EGFR-R/HER2, Src, Akt, Raf, MEK, Bcr-Abl, Flt-3, etc.,); ii) An ability to evade apoptosis (mutated form of p53, Akt, survivin, etc.,); iii) An insensitivity to proliferation stop signal(Cdk4, Plk, Wee1, etc.,); iv) An ability to activate angiogenesis (VEGF-R, FAK, HIF-1, Akt, etc.,); v) An ability to proliferate with no replicative limit (hTert, etc.,); vi) An ability to evade new tissue and to metastasize(c-Met);(Hanahan D. and Weinberg R.A., Cell (2002), 100, 57-70). Therefore, the client protein-induced tumor formation can be blocked by inhibition of HSP90 activity.
- the first known HSP90 inhibitors are compounds of the ansamycin family, in particular geldanamycin and herbimycin A. X-ray studied have shown that geldanamycin binds to the ATP site of the N-terminal domain of HSP90, where it inhibits the ATPase activity of the chaperone (Prodromou C. et al, Cell (1997), 90, 65-75). Currently, the NIH and Kosan BioScience are carrying out the clinical development of 17AAG, which is a geldanamycin-derived HSP90 inhibitor.
- Radicicol is also a Hsp90 inhibitor of natural origin ([Roe S.M. et al, J. Med Chem. (1999),42, 260-66]).
- Hsp90 inhibitor of natural origin novobiocin
- Purines such as the compound PU3 ([Chiosis et al, Chem. Biol. (2001),8, 289-299]), have also been described as small molecule Hsp90 inhibitors.
- analogues such as 8-heteroaryl-6-phenylimidazo [1,2-a]pyrazines (WO 2004/072080), pyrazole derivatives (WO 2004/050087), isoxazole derivatives (WO 2004/07051) and benzophonone derivatives (WO 2005/00778) have also been described as HSP90 inhibitor, that are useful for the treatment of tumors.
- HSP90 inhibitors involve binding to HSP90 at the ATP binding site located in the N-terminal domain of the protein, leading to inhibition of the intrinsic ATPase activity of HSP90. Inhibition of HSP90 ATPase activity prevents recruitment of co-chaperons, which these client proteins are targeted for degradation via the ubiquitin proteasome pathway.
- An attractive rationale for developing drugs against this target for use in the clinic is that by simultaneously depleting tumor and associated with the client proteins, one may obtain a strong antitumor effect and achieve a therapeutic advantage against cancer versus normal cells.
- the compound of Formula II has high activities in vitro, but it has low solubility in water. As a result, many problems like low bioavailability and pharmacokinetic parameter are caused for developing medicine.
- the compound of Formula I of the present invention fulfill all requirements of good prodrug and have significantly improved the feature in solubility and pharmacokinetic property.
- this present invention is designed to provide a novel prodrug of 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide, the compound of Formula II, having to improve pharmacokinetic property
- the present invention provides the novel compound of Formula I.
- both R 1 and R 2 are PO(OH) 2 or , or wherein R 1 or R 2 is hydrogen and the other R 1 or R 2 is , PO(OH) 2 or , wherein M is Na + , K + , Mg 2+ , or Ca 2+ , and n is 1 or 2, wherein n is 1 and M is Mg 2+ or Ca 2+ , or wherein n is 2 and M is Na + or K + .
- Particularly preferred examples of the compound of Formula I according to the present invention include the following.
- the present invention provides a process for preparing a compound of Formula I.
- the compound of Formula I of the present invention can be prepared by a series of steps from the compound of Formula II, parent drug.
- the compound of Formula II used as a start substance can be prepared using a known preparation process(WO 2011/102660).
- the compound of Formula Ia can be prepared R 1 or R 2 is by deprotection with HCl after synthesizing with intermediate compound, boc(tert-butoxy carbonyl) protected lysine by esterification the compound of Formula II with Boc-Lys(Boc)-OH in methylene chloride solvent.
- R 1 and R 2 are differently selected from each other hydrogen or .
- the reaction scheme as below shows an example according to the process for preparation as above.
- the compound of Formula Ib, wherein R 1 and/or R 2 are PO(OH) 2 can be prepared by hydrolysis reaction with trifluoroacetic acid or HCl after synthesizing bis(tetramethylphosphorodiamidate)-intermediate compound by substitution reaction of the compound of Formula II with tetramethylphsphorodiamidic chloride in H 2 O or dioxane solvent.
- R 1 and R 2 are both PO(OH) 2 , or wherein R 1 and R 2 are differently selected from each other hydrogen or PO(OH) 2 .
- the reaction scheme as below shows an example according to the process for preparation as above.
- the compound of Formula Ic as below wherein R 1 and/or R 2 are/is can be prepared by base reaction of the compound of Formula Ib as above with inorganic base, NaOH, KOH, Ca(OH) 2 , or Mg(OH) 2 .
- the compound of Formula II, the compound of salt as above, can be included in the compound of Formula I according to the present invention
- R 1 and R 2 are both , or wherein R 1 and R 2 are differently selected from each other hydrogen or , wherein n and M are defined in Formula I.
- reaction formula as below shows an example according to according to the process for preparation as above.
- the compound of Formula I may be used as a prodrug of the parent compound of Formula II, which process valuable pharmacological properties.
- the compound of Formula I have improved solubility by 1,000 ⁇ 20,000 times or more, and increased bioavailability compared to the compound of Formula II. Furthermore, the compound of Formula I can be absorbed into the body with increased concentration by improved value of AUC 0-120min and C max , more by 3 ⁇ 5 times and 10 ⁇ 20 times respectively compared to the compound of Formula II and can be improved pharmacokinetic properties.
- the compound represented by the parent drug of Formula II could be useful in the treatment of diseases which are responsive to inhibition of HSP90 activity such as immunosupression, Rheumatoid arthritis, Asthma, MS, Type I Diabetes, Lupus, Psoriasis, inflammatory Bowel Diseases, viral Diseases; diabetic retinopathy, hemangiomas, endometriosis; normal cells protection against chemotherapy-induced toxicity; protection from hypoxia-ischemic injury due to elevation of HSP70 in the heart and brain, scrapie/CJD, Huntingdon's and Alzhiemer's. Especially, it could be useful in the treatment of cancer.
- diseases which are responsive to inhibition of HSP90 activity such as immunosupression, Rheumatoid arthritis, Asthma, MS, Type I Diabetes, Lupus, Psoriasis, inflammatory Bowel Diseases, viral Diseases; diabetic retinopathy, hemangiomas, endometriosis; normal cells protection against chemotherapy-induced toxicity;
- the compound of Formula I prodrug which involved variable functional group induced resorcinol derivatives, show effective anti-tumor activity in the many cancer cell line.
- a pharmaceutical composition of the present invention for use in the treatment of cancer can be administered by any convenient passage; for example, oral, paranteral, oral cavity, hypoglossal, the nasal cavity, rectal, and hypodermic administration, and can be prepared by containing pharmaceutically acceptable excipient and the compound of Formula I.
- the doses of pharmaceutical composition of the present invention may vary depending on the patient's weight, age, gender, physical condition, diet, the time and mode of administration, excretion rates, and the severity of illness.
- the doses of detailed drug composition may be administered in an effective amount ranging from 0.1 to 1000mg on adult.
- the present invention provides the novel compound of Formula I.
- the compound of Formula I are used as a prodrug of the parent compound, Formula II, which process valuable pharmacological properties.
- the compound of Formula I have improved solubility by 1,000 ⁇ 20,000 times or more, and increased bioavailability compared to those of the compound of Formula II. Furthermore, they can be absorbed into the body with increased concentration by improved value of AUC 0-120min and C max , more by 3 ⁇ 5 times and 10 ⁇ 20 times respectively compared to the compound of Formula II. Thus, those improved pharmacokinetic properties can be used very effectively to treat various diseases by inhibition of HSP90 activity, especially for ovarian and gastric cancer.
- Step 1 4-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-6-isopropyl-1,3-phenylenebis(tetramethylphosphorodiamidate)
- step 2 4-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-6-isopropyl-1,3-penylene bis(dihydrogen phosphate)
- the intermediate compound(Step 1)(428mg, 0.67mmol) was dissolved in trifluoroacetic acid(1.8ml)/H 2 O(0.2ml). The reaction mixture was stirred at RT for overnight. Solvents were removed in vacuo, and methanol was added to the mixture. The mixture was filtered through a pad of Celite, and the filtrate was concentrated. The residue was diluted by water and washed by ethyl acetate. The aqueous phase was evaporated in vacuo. The residue was purified by Dowex 50WX4 cation exchange resin to afford the title compound (250mg, 0.47mmol) in a yield 70%.
- Step 1 (S)-2-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl2,6- bis((tertbutoxycarbonyl)amino)hexanoate (I-9)
- Step 2 (S)-2-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl2,6-diaminohexanoate dihydrochloride (I-10)
- Step 1 5-(4-(Ethoxymethoxy)-2-hydroxy-5-isopropylphenyl)-N-ethyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide
- Step 2 5-(Ethoxymethoxy)-2-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-4-isopropylphenyltetramethyl phosphorodiamidate
- the intermediate compound(Step 1)(1.40g, 3.26mmol) was dissolved in methylene chloride(40ml). 4-(dimethylamino)pyridine(199mg, 1.63mmol), 1,8-diazabicyclo[5.4.0]-undec-7-ene(0.56ml, 3.91mmol) and tetramethylphosphorodiamidic chloride(0.56ml, 3.91mmol) were added sequentially. The reaction mixture was stirred at RT for overnight. And the residue was extracted by methylene chloride after the reaction was completed by saturated ammonium chloride. The organic phase was washed by brine, was dried with magnesium sulfate, and was evaporated in vacuo.
- Step 3 2-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl dihydrogen phosphate
- Step 2 The intermediate compound (Step 2)(1.82g, 3.23mmol) was dissolved in 1,4-dioxane(100ml) was added to 12N HCl(100ml). The reaction mixture was stirred at RT for 3h, and evaporated in vacuo. After the solvent and HCl were removed, the residue was purified by reversed phase chromatography to afford the title compound(1.10g, 2.42mmol)in a yield of 75%.
- Step 1 5-(2-(Ethoxymethoxy)-4-hydroxy-5-isopropylphenyl)-N-ethyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide
- Step 2 5-(Ethoxymethoxy)-4-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-2-isopropylphenyltetramethyl phosphorodiamidate
- the intermediate compound(Step 1)(3.02g, 7.01mmol) was dissolved in methylene chloride(80ml). 4-(dimethylamino)pyridine(428mg, 3.50mmol), 1,8-diazabicyclo[5.4.0]-unde-7-sen(1.21ml, 8.41mmol) and tetramethylphosphorodiamidic chloride(1.21ml, 8.41mmol) were added sequentially. The reaction mixture was stirred at RT for overnight. And the residue was extracted between methylene chloride, was saturated ammonium chloride and was washed by brine. The organic phase was dried with magnesium sulfate, and evaporated in vacuo.
- Step 3 4-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-2-isopropylphenyl dihydrogen phosphate
- the intermediate compound(Step 2) (3.95g, 6.99mmol) was dissolved in 1,4-dioxane(200ml), 12N HCl(200ml) was added. The reaction mixture was stirred at RT for 3h, and evaporated in vacuo. After concentrated by decompression, the residue was purified by reversed phase chromatography to afford the intermediate compound(2.53g, 5.59mmol) in a yield of 80%.
- the compound of Formula I and the compound of Formula II(parent compound) were dissolved respectively in deionized water.
- the solution was vigorously stirred for 30 seconds at 20 ⁇ 5°C every 5 minutes and the solubility tests were performed within 30 minutes.
- the compound of Formula II can be a practically insoluble compound.
- the present invention relates to the compound of Formula I which shows significant improvement in solubility because the solubility of the compound of Formula I was 1,000 to 20,000 times higher than that of the compound of Formula II(parent compound).
- modified physicochemical characteristics of the compound of Formula I may have positive effects on both developing formulations for a drug candidate and increasing bioavailability, due to its enhanced solubility.
- Liquid-liquid extraction with ethyl acetate was used for plasma sample preparation.
- LC-MS/MS analysis was conducted to analyze the compound of Formula I and Formula II(parent compound).
- Pharmacokinetic parameters were determined by noncompartmental analysis(WinNonLin®), and PK results are given as shown in Table 2.
- AUC 0-120min (Area under the plasma concentration-time curve) and C max of the compound of Formula II(parent compound) were 33,529 ng ⁇ min ⁇ ml -1 and 420 ng/ml, respectively.
- AUC 0-120min of the compound of Formula I was 3 to 5 times higher than that of the compound of Formula II as compared to its parent compound on a molecular weight and doses.
- the compound of Formula I was absorbed more rapidly than its parent compound because C max of the compound of Formula I was 10 to 20 times higher than that of the compound of Formula II(parent compound) as compared to its parent drug on a molecular weight and doses.
- the present invention relates to the compound of Formula I which displays much more improved PK profile than the compound of Formula II( parent compound).
- the compound of Formula I (I-1, I-2, I-3, I-7) were formulated in deionized water and administered orally (po) at a dose of 200mg/kg. The vehicle alone was administered to control groups. Animals were dosed 5 days per week (Monday through Friday) for 2 consecutive weeks.
- TGI Tumor growth inhibition
- TGI(%) (1-DT/DC) x 100
- DT and DC represent the mean tumor volume changes in treatment and control groups, respectively.
- the compound of Formula I significantly inhibited tumor growth in vivo.
- the novel compound of Formula I exhibits more improved solubility by approximately 1,000 to 20,000 times compared to the compound of Formula II(parent compound). Moreover, the compound of Formula I has more favorable PK profile. As compared to its parent drug on a molecular weight and doses, AUC 0-120min and C max of the compound of Formula I were 3 to 5 times and 10 to 20 times higher than those of the compound of Formula II, respectively. Therefore, the improved PK profile of the compound of Formula I can be useful in developing a new anticancer drug candidate.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
The present invention relates to the novel compound of Formula I. The compound of Formula I are used as a prodrug of the parent compound, Formula II, and have valuable pharmacological properties. The compound of Formula I have improved solubility by 1,000~20,000 times or more, and increased bioavailability compared to those of the compound of Formula II. Furthermore, they can be absorbed into the body with increased concentration by improved value of AUC0-120min and Cmax, more by 3~5 times and 10~20 times respectively compared to the compound of Formula II. Thus, those improved pharmacokinetic properties can be used very effectively to treat various diseases by inhibition of HSP90 activity, especially for ovarian and gastric cancer.
Description
This present invention relates to the compound of Formula I.
<Formula Ⅰ>
wherein,
both R1 and R2 are PO(OH)2 or , or wherein R1 or R2 is hydrogen and the other R1 or R2 is , PO(OH)2 or , wherein M is Na+, K+, Mg2+, or Ca2+, and n is 1 or 2, wherein n is 1 and M is Mg2+ or Ca2+ , or wherein n is 2 and M is Na+ or K+.
It has been found that the compound of Formula Ⅰ may be as a prodrug of the compound of Formula Ⅱ, 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide, which is HSP90 inhibitory activity, is stated in the following patent, WO 2011/102660.
<Formula Ⅱ>
A prodrug is in most cases a pharmacologically inactive derivative of a parent drug molecule that requires spontaneous or enzymatic transformation within the body in order to release the active drug, and that has improved delivery properties over the parent drug molecule. It has been shown that a molecule with optimal structural configuration and physicochemical properties for eliciting the desired therapeutic response at its target site does not necessarily possess the best molecular from and properties for its delivery to its point of ultimate action. Usually, only a minor fraction of doses administered reaches the target area and since most agents interact with non-target sites as well, an inefficient delivery may result in undesirable side effects. This fact of differences in transport and in situ effect characteristics for many drug molecules is the basic reason why bioreversible chemical derivatization of drugs, i.e., prodrug formation is a means by which a substantial improvement in the overall efficacy of drugs can often be achieved. Prodrugs are designed to overcome pharmaceutically and/or pharmacokinetically based problems associated with the parent drug molecule.
In recent years several types of bioreversible derivatives have been exploited for utilization in designing prodrugs. Using esters as a prodrug type for drugs containing carboxyl or hydroxyl functional group is most popular. Further well-known are prodrug derivatives of peptides, 4-imidazolidinones and the like, described in Drugs of the Future, 1991, 16(5), 443-458 or N-oxides, described for example in US 5.691.336.
On the other hand, molecular chaperones are a general term for proteins that form a complex temporally with client proteins to promote the formation of the conformation of the client proteins. These proteins, the activity of which is to help folding and association of protein and to prevent aggregation are broadly defined as molecular chaperones.
Exposure of cells to a number of environmental stresses, including heat shock, alcohol, heavy metals and oxidative stress, results in the cellular accumulation of a number of chaperones, commonly known as heat shock proteins (HSPs). Molecular chaperones of the "heat shock proteins" family (HSPs), classified according to their molecular mass (HSP70, HSP90, HSP27, etc.,), protect the cell against the initial stress, enhances recovery and leads to maintenance of a stress tolerant state. It has also become clear, however, that certain HSPs may also play a major molecular chaperone role under normal, stress-free conditions by regulating the correct folding, degradation, localization and function of a growing list of important cellular proteins.
Several diseases in humans can be acquired as a result of protein misfolding. In some conditions (e.g., Alzheimer's disease, prion diseases and Huntington's disease), misfolded proteins can cause protein aggregation resulting in neurodegenerative disorders ([Tytell M. and Hooper P.L., Emerging Ther. Targets (2001), 5, 3788-3796]). HSPs, and in particular HSP90, are also involved in the regulation of various major functions of the tumor cell, via their association with various client proteins involved in cell proliferation or apoptosis. In these pathologies, approaches aimed at breaking up or at disturbing the function of chaperones could be available for treatment of disease. Especially, HSP90 chaperons has recently been demonstrated as a particularly promising target in anticancer therapy ([Moloney A. and Workman P., Expert Opin. Biol. Ther. (2002), 2(1), 3-24]; [Choisis et al, Drug Discovery Today (2004), 9, 881-888]).
HSP90 (Heat Shock Protein 90) family proteins included HSP90α HSP90β GRP94 and HSP75/TRAP1. These proteins represent approximately 1-2% of the total cellular protein mass. It is usually in the form of a dimer in the cell and is associated with multiplicity of proteins, so-called co-chaperones. HSP90 plays a key role in the response to cellular stress by interaction with many proteins whose native folding has been modified by external stress, such as, for example, heat shock, in order to restore the original folding or to prevent aggregation of the proteins ([Smith D.F. et al., Pharmacological Rev. (1998), 50, 493-513]). There are also indications that HSP90 is of importance as buffer against the effects of mutations, presumably through correction of incorrect protein folding caused by the mutation ([Rutherford and Lindquist, 1998]). HSP90 also has a regulatory importance. Under physiological conditions, HSP90, together with its homologue in the endoplasmatic reticulum, GRP94, plays a role in the cell balance for ensuring the stability of the conformation and maturing of various client key proteins, such as, EGFR R/HER2, Src, Akt, Raf, MEK, Bcr-Abl, Flt-3, mutated p53, Akt, survivin, Cdk4, Plk, Wee1, VEGF-R, FAK, HIF-1, hTert and c-Met, etc. These client proteins are involved in the six mechanisms of tumour progression. i) An ability to proliferate in the absence of growth factor(EGFR-R/HER2, Src, Akt, Raf, MEK, Bcr-Abl, Flt-3, etc.,); ii) An ability to evade apoptosis (mutated form of p53, Akt, survivin, etc.,); iii) An insensitivity to proliferation stop signal(Cdk4, Plk, Wee1, etc.,); iv) An ability to activate angiogenesis (VEGF-R, FAK, HIF-1, Akt, etc.,); v) An ability to proliferate with no replicative limit (hTert, etc.,); vi) An ability to evade new tissue and to metastasize(c-Met);(Hanahan D. and Weinberg R.A., Cell (2002), 100, 57-70). Therefore, the client protein-induced tumor formation can be blocked by inhibition of HSP90 activity.
The first known HSP90 inhibitors are compounds of the ansamycin family, in particular geldanamycin and herbimycin A. X-ray studied have shown that geldanamycin binds to the ATP site of the N-terminal domain of HSP90, where it inhibits the ATPase activity of the chaperone (Prodromou C. et al, Cell (1997), 90, 65-75). Currently, the NIH and Kosan BioScience are carrying out the clinical development of 17AAG, which is a geldanamycin-derived HSP90 inhibitor.
Radicicol is also a Hsp90 inhibitor of natural origin ([Roe S.M. et al, J. Med Chem. (1999),42, 260-66]). However, although the latter is by far the best in vitro HSP90 inhibitor, its metabolic instability with respect to sulphur-containing nucleophiles makes it difficult to use in vivo. One Hsp90 inhibitor of natural origin, novobiocin, binds to a different ATP site located in the C-terminal domain of the protein ([Itoh H. et al, Biochem J. (1999), 343, 697-703]). Purines, such as the compound PU3 ([Chiosis et al, Chem. Biol. (2001),8, 289-299]), have also been described as small molecule Hsp90 inhibitors.
In addition, the analogues, such as 8-heteroaryl-6-phenylimidazo [1,2-a]pyrazines (WO 2004/072080), pyrazole derivatives (WO 2004/050087), isoxazole derivatives (WO 2004/07051) and benzophonone derivatives (WO 2005/00778) have also been described as HSP90 inhibitor, that are useful for the treatment of tumors.
The known HSP90 inhibitors involve binding to HSP90 at the ATP binding site located in the N-terminal domain of the protein, leading to inhibition of the intrinsic ATPase activity of HSP90. Inhibition of HSP90 ATPase activity prevents recruitment of co-chaperons, which these client proteins are targeted for degradation via the ubiquitin proteasome pathway. An attractive rationale for developing drugs against this target for use in the clinic is that by simultaneously depleting tumor and associated with the client proteins, one may obtain a strong antitumor effect and achieve a therapeutic advantage against cancer versus normal cells.
A cited compound in the present invention, the compound of Formula Ⅱ, 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide, having a HSP90 inhibitory activity, is stated in the following patent, WO 2011/102660.
The compound of Formula II has high activities in vitro, but it has low solubility in water. As a result, many problems like low bioavailability and pharmacokinetic parameter are caused for developing medicine.
However, it has been shown that the compound of Formula I of the present invention fulfill all requirements of good prodrug and have significantly improved the feature in solubility and pharmacokinetic property.
Accordingly, this present invention is designed to provide a novel prodrug of 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide, the compound of Formula Ⅱ, having to improve pharmacokinetic property
To solve the problem described above, the present invention provides the novel compound of Formula I.
<Formula I>
wherein,
both R1 and R2 are PO(OH)2 or , or wherein R1 or R2 is hydrogen and the other R1 or R2 is , PO(OH)2 or , wherein M is Na+, K+, Mg2+, or Ca2+, and n is 1 or 2, wherein n is 1 and M is Mg2+ or Ca2+ , or wherein n is 2 and M is Na+ or K+.
Particularly preferred examples of the compound of Formula I according to the present invention include the following.
4-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-6-isopropyl-1,3-phenylene bis(dihydrogen phosphate); (I-1)
(S)-2-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl 2,6-diaminohexanoate dihydrochloride; (I-2)
Sodium 4-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-6-isopropyl-1,3-phenylene diphosphate; (I-3)
2-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl dihydrogen phosphate; (I-4)
Sodium 2-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl phosphate; (I-5)
4-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-2-isopropylphenyl dihydrogen phosphate; (I-6)
Sodium 4-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-2-isopropylphenyl phosphate; (I-7)
Potassium 4-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-6-isopropyl-1,3-phenylene diphosphate; (I-8)
Potassium 2-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl phosphate; (I-9)
Potassium 4-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-2-isopropylphenyl phosphate; (I-10)
Calcium 4-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-6-isopropyl-1,3-phenylene diphosphate; (I-11)
Calcium 2-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl phosphate; (I-12)
Calcium 4-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-2-isopropylphenyl phosphate; (I-13)
Magnesium 4-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-6-isopropyl-1,3-phenylene diphosphate; (I-14)
Magnesium 2-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl phosphate; (I-15)
Magnesium 4-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-2-isopropylphenyl phosphate; (I-16)
In another aspect, the present invention provides a process for preparing a compound of Formula I.
A process for preparing a compound of Formula I is shown in the following scheme 1.
<scheme 1>
The compound of Formula I of the present invention, as shown in scheme 1, can be prepared by a series of steps from the compound of Formula Ⅱ, parent drug.
Each steps of the above preparation process is described in more detail as follows.
1) Preparing the compound of Formula Ⅱ
The compound of Formula Ⅱ used as a start substance can be prepared using a known preparation process(WO 2011/102660).
2) Preparing the compound of Formula I
First of all, the compound of Formula Ia can be prepared R1 or R2 is
by deprotection with HCl after synthesizing with intermediate compound, boc(tert-butoxy carbonyl) protected lysine by esterification the compound of Formula II with Boc-Lys(Boc)-OH in methylene chloride solvent.
<Formula Ia>
The reaction scheme as below shows an example according to the process for preparation as above.
Secondly, the compound of Formula Ib, wherein R1 and/or R2 are PO(OH)2 can be prepared by hydrolysis reaction with trifluoroacetic acid or HCl after synthesizing bis(tetramethylphosphorodiamidate)-intermediate compound by substitution reaction of the compound of Formula II with tetramethylphsphorodiamidic chloride in H2O or dioxane solvent.
<Formula Ib>
wherein R1 and R2 are both PO(OH)2, or wherein R1 and R2 are differently selected from each other hydrogen or PO(OH)2.
The reaction scheme as below shows an example according to the process for preparation as above.
Thirdly, the compound of Formula Ic as below wherein R1 and/or R2 are/is , can be prepared by base reaction of the compound of Formula Ib as above with inorganic base, NaOH, KOH, Ca(OH)2, or Mg(OH)2. The compound of Formula II, the compound of salt as above, can be included in the compound of Formula I according to the present invention
<Formula Ic>
wherein R1 and R2 are both , or wherein R1 and R2 are differently selected from each other hydrogen or , wherein n and M are defined in Formula I.
The reaction formula as below shows an example according to according to the process for preparation as above.
As mentioned earlier, the compound of Formula I may be used as a prodrug of the parent compound of Formula II, which process valuable pharmacological properties.
The compound was examined in accordance with the test given hereinafter. The evidence, that the compound of Formula I can be used as prodrugs of their parent compound of Formula II is shown in accordance with the description given hereinafter.
The compound of Formula I have improved solubility by 1,000~20,000 times or more, and increased bioavailability compared to the compound of Formula II. Furthermore, the compound of Formula I can be absorbed into the body with increased concentration by improved value of AUC0-120min and Cmax, more by 3~5 times and 10~20 times respectively compared to the compound of Formula II and can be improved pharmacokinetic properties.
The compound represented by the parent drug of Formula Ⅱ could be useful in the treatment of diseases which are responsive to inhibition of HSP90 activity such as immunosupression, Rheumatoid arthritis, Asthma, MS, Type I Diabetes, Lupus, Psoriasis, inflammatory Bowel Diseases, viral Diseases; diabetic retinopathy, hemangiomas, endometriosis; normal cells protection against chemotherapy-induced toxicity; protection from hypoxia-ischemic injury due to elevation of HSP70 in the heart and brain, scrapie/CJD, Huntingdon's and Alzhiemer's. Especially, it could be useful in the treatment of cancer.
Therefore, in this invention, the compound of Formula I, prodrug which involved variable functional group induced resorcinol derivatives, show effective anti-tumor activity in the many cancer cell line.
A pharmaceutical composition of the present invention for use in the treatment of cancer can be administered by any convenient passage; for example, oral, paranteral, oral cavity, hypoglossal, the nasal cavity, rectal, and hypodermic administration, and can be prepared by containing pharmaceutically acceptable excipient and the compound of Formula I.
The doses of pharmaceutical composition of the present invention may vary depending on the patient's weight, age, gender, physical condition, diet, the time and mode of administration, excretion rates, and the severity of illness. The doses of detailed drug composition may be administered in an effective amount ranging from 0.1 to 1000㎎ on adult.
The present invention provides the novel compound of Formula I. The compound of Formula I are used as a prodrug of the parent compound, Formula II, which process valuable pharmacological properties.
The compound of Formula I have improved solubility by 1,000~20,000 times or more, and increased bioavailability compared to those of the compound of Formula II. Furthermore, they can be absorbed into the body with increased concentration by improved value of AUC0-120min and Cmax, more by 3~5 times and 10~20 times respectively compared to the compound of Formula II. Thus, those improved pharmacokinetic properties can be used very effectively to treat various diseases by inhibition of HSP90 activity, especially for ovarian and gastric cancer.
The present invention will be described more particularly by the Examples but the present invention is not limited at all by these examples.
Example 1 4-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-6-isopropyl-1,3-phenylene bis(dihydrogen phosphate) (I-1)
Step 1: 4-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-6-isopropyl-1,3-phenylenebis(tetramethylphosphorodiamidate)
5-(2,4-Dihydroxy-5-isopropylphenyl)-N-ethyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide(250㎎, 0.67mmol) was dissolved in methylene chloride(7㎖). Tetramethylphosphorodiamidic chloride(0.35㎖, 2.35mmol), 4-(dimethylamino)pyridine(41㎎, 0.34mmol) and 1,8-diazabicylco{5.4.0]undec-7-ene(0.25㎖, 1.68mmol) were added sequentially. The reaction mixture was stirred at RT for overnight. Saturated ammonium chloride was added to the mixture. The residue was extracted between methylene chloride and water. The organic phase was washed water, brine, dried with magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography to afford the intermediate compound 4-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-6-isopropyl-1,3-phenylene bis(tetramethylphosphorodiamidate)(428㎎, 0.67mmol) in a yield 99%.
1H-NMR (400 MHz, CDCl3) δ 7.54 (s, 1H), 7.44 (s, 1H), 6.97 (br t, 1H), 3.49 (m, 2H), 3.27 (sept, 1H), 2.80 (s, 6H), 2.77 (s, 6H), 2.66 (s, 6H), 2.63 (s, 6H), 2.61 (s, 3H), 1.26 (t, 3H), 1.19 (d, 6H)
step 2: 4-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-6-isopropyl-1,3-penylene bis(dihydrogen phosphate)
The intermediate compound(Step 1)(428㎎, 0.67mmol) was dissolved in trifluoroacetic acid(1.8㎖)/H2O(0.2㎖). The reaction mixture was stirred at RT for overnight. Solvents were removed in vacuo, and methanol was added to the mixture. The mixture was filtered through a pad of Celite, and the filtrate was concentrated. The residue was diluted by water and washed by ethyl acetate. The aqueous phase was evaporated in vacuo. The residue was purified by Dowex 50WX4 cation exchange resin to afford the title compound (250㎎, 0.47mmol) in a yield 70%.
1H-NMR (400 MHz, D2O) δ 7.49 (s, 1H), 7.22 (s, 1H), 3.35 (q, 2H), 3.24 (sept, 1H), 2.50 (s, 3H), 1.14 (t, 3H), 1.11 (d, 6H)
Example 2 (S)-2-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl2,6-diaminohexanoate dihydrochloride (I-2)
Step 1:(S)-2-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl2,6-
bis((tertbutoxycarbonyl)amino)hexanoate (I-9)
5-(2,4-Dihydroxy-5-isopropylphenyl)-N-ethyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide(138㎎, 0.37mmol) was dissolved in DMF(3.0㎖). 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide(248㎎, 1.29mmol), 4-(dimethylamino)pyridine(22㎎, 0.19mmol) and Boc-Lys(Boc)-OH(384㎎, 1.11mmol) were added sequentially. The reaction mixture was stirred at RT for 12h. The residue was evaporated in vacuo and purified by silica gel column chromatography to afford the intermediate compound (S)-2-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl 2,6-bis((tert-butoxycarbonyl)amino)hexanoate(200㎎, 0.19mmol) in a yield 53%.
1H-NMR (400 MHz, CDCl3) δ 7.65 (s, 1H), 7.43 (s, 1H), 5.21 (br, 2H), 4.55 (br, 2H), 4.40 (br, 2H), 3.48 (m, 2H), 3.18-3.06 (m, 3H), 2.67 (s, 3H), 1.98 (br, 2H), 1.84 (br, 1H), 1.48 (m, 18H), 1.28-1.23 (m, 9H)
Step 2: (S)-2-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl2,6-diaminohexanoate dihydrochloride (I-10)
To a solution of the intermediate compound(Step 1)(50㎎, 0.05mmol) in CH3CN(2㎖) was added 4.0M HCl in dioxane(0.4㎖, 1.46mmol). The reaction mixture was stirred at RT for 12h. The reaction mixture was evaporated in vacuo to afford the title compound(28㎎, 0.05mmol) in a yield 99%.
1H-NMR (400 MHz, CDCl3) δ 7.85 (s, 1H), 7.58 (s, 1H), 4.55 (m, 1H), 4.31 (m, 1H), 3.44 (m, 2H), 3.41 (m, 3H), 3.13 (m, 1H), 3.04-2.95 (m, 5H), 2.61 (s, 3H), 1.82 (m, 2H), 1.73 (m, 1H), 1.28-1.21 (m, 9H)
Example 3
Sodium 4-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-6-isopropyl-1,3-phenylene diphosphate (I-3)
4-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl dihydrogen phosphate(4.90g, 9.20mmol) was dissolved in H2O(350㎖). 1N NaOH(36.59㎖, 36.59mmol) was added. The reaction mixture was stirred at RT for 30 min, and evaporated in vacuo to afford the title compound(5.63g, 9.08mmol) in a yield of 99%.
1H-NMR (400 MHz, D2O) δ 7.40 (s, 1H), 7.33 (s, 1H), 3.46 (q, 2H), 3.38 (m, 1H), 2.63 (s, 3H), 1.26 (t, 3H), 1.16 (d, 6H)
Example 4
2-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl dihydrogen phosphate (I-4)
Step 1: 5-(4-(Ethoxymethoxy)-2-hydroxy-5-isopropylphenyl)-N-ethyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide
To a solution of 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide(5.0g, 13.4mmol) in acetone(300㎖) cooled to 0℃ was added triethylamine(2.25㎖, 16.1mmol) and ethoxymethyl chloride(1.31㎖, 14.1mmol) sequentially, and the reaction mixture was stirred at RT for overnight. Solvent was evaporated in vacuo, and the residue was extracted between ethyl acetate and brine. The organic phase was dried with anhydrous magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography to afford the intermediate compound 5-(4-(ethoxymethoxy)-2-hydroxy-5-isopropylphenyl)-N-ethyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide(1.40g, 3.26mmol) in a yield of 24.3%.
1H-NMR (400 MHz, CDCl3) δ 7.44 (s, 1H), 6.99(brt, 1H), 6.67 (s, 1H), 5.87 (s, 1H), 4.90 (s, 2H), 3.54-3.45 (m, 4H), 3.10 (sept, 1H), 2.60 (s, 3H), 1.38-1.21 (m, 12H).
Step 2: 5-(Ethoxymethoxy)-2-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-4-isopropylphenyltetramethyl phosphorodiamidate
The intermediate compound(Step 1)(1.40g, 3.26mmol) was dissolved in methylene chloride(40㎖). 4-(dimethylamino)pyridine(199㎎, 1.63mmol), 1,8-diazabicyclo[5.4.0]-undec-7-ene(0.56㎖, 3.91mmol) and tetramethylphosphorodiamidic chloride(0.56㎖, 3.91mmol) were added sequentially. The reaction mixture was stirred at RT for overnight. And the residue was extracted by methylene chloride after the reaction was completed by saturated ammonium chloride. The organic phase was washed by brine, was dried with magnesium sulfate, and was evaporated in vacuo. After concentrated with decompression, the residue was purified by silica gel column chromatography to afford the intermediate compound 5-(ethoxymethoxy)-2-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-4-isopropylphenyltetramethyl phosphorodiamidate(1.82g, 3.23mmol) in a yield of 99%.
1H-NMR (400 MHz, CDCl3) δ 7.52 (s, 1H), 7.23 (s, 1H), 6.98 (brt, 1H), 4.93 (s, 2H), 3.52-3.43 (m, 4H), 3.26 (sept, 1H), 2.77 (s, 6H), 2.74 (s, 6H), 2.60 (s, 3H), 1.27-1.22 (m, 9H), 1.18(t, 3H)
Step 3: 2-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl dihydrogen phosphate
The intermediate compound (Step 2)(1.82g, 3.23mmol) was dissolved in 1,4-dioxane(100㎖) was added to 12N HCl(100㎖). The reaction mixture was stirred at RT for 3h, and evaporated in vacuo. After the solvent and HCl were removed, the residue was purified by reversed phase chromatography to afford the title compound(1.10g, 2.42mmol)in a yield of 75%.
1H-NMR (400 MHz, D2O) δ 7.33 (s, 1H), 6.79 (s, 1H), 3.30 (q, 2H), 3.07 (sept, 1H), 2.47 (s, 3H), 1.10 (t, 3H), 1.04(d, 6H)
Example 5
Sodium 2-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl phosphate (I-5)
2-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl dihydrogen phosphate(60mg, 0.13mmol) was dissolved in H2O(4.8㎖). 1N NaOH(0.26㎖, 0.26mmol) was added. The reaction mixture was stirred at RT for 30 min, and evaporated in vacuo. The solvent was concentrated by decompression and was removed to afford the title compound(66㎎, 0.13mmol) in a yield of 99%.
1H-NMR (400 MHz, D2O) δ 7.22 (s, 1H), 6.96 (s, 1H), 3.33 (q, 2H), 3.06 (sept, 1H), 2.49 (s, 3H), 1.12 (t, 3H), 1.02 (d, 6H)
Example 6
4-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-2-isopropylphenyl dihydrogen phosphate (I-6)
Step 1: 5-(2-(Ethoxymethoxy)-4-hydroxy-5-isopropylphenyl)-N-ethyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide
To a solution of 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide(5.0g, 13.4mmol) in acetone(300㎖) cooled to 0℃ was added Cs2CO3(5.25g, 16.1mmol), and ethoxymethyl chloride(1.31㎖, 14.1mmol) sequentially. The reaction mixture was stirred at RT for overnight. Solvent was evaporated in vacuo, and the residue was extracted between ethyl acetate and brine. The organic phase was dried with magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography to afford the intermediate compound 5-(2-(ethoxymethoxy)-4-hydroxy-5-isopropylphenyl)-N-ethyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide(3.02g, 7.01mmol) in a yield of 52.3%.
1H-NMR (400 MHz, CDCl3) δ 7.42 (s, 1H), 6.64 (s, 1H), 5.85 (s, 1H), 4.89 (s, 2H), 3.52~3.44 (m, 4H), 3.15~3.09 (m, 1H), 2.60 (s, 3H), 1.64 (s, 3H), 1.35~1.05 (m, 16H), 0.90~0.82 (m, 2H).
Step 2: 5-(Ethoxymethoxy)-4-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-2-isopropylphenyltetramethyl phosphorodiamidate
The intermediate compound(Step 1)(3.02g, 7.01mmol) was dissolved in methylene chloride(80㎖). 4-(dimethylamino)pyridine(428㎎, 3.50mmol), 1,8-diazabicyclo[5.4.0]-unde-7-sen(1.21㎖, 8.41mmol) and tetramethylphosphorodiamidic chloride(1.21㎖, 8.41mmol) were added sequentially. The reaction mixture was stirred at RT for overnight. And the residue was extracted between methylene chloride, was saturated ammonium chloride and was washed by brine. The organic phase was dried with magnesium sulfate, and evaporated in vacuo. After concentrated by decompression, the residue was purified by silica gel column chromatography to afford the intermediate compound 5-(ethoxymethoxy)-4-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-2-isopropylphenyltetramethyl phosphorodiamidate(3.95g, 6.99mmol) in a yield of 99%.
1H-NMR (400 MHz, CDCl3) δ 7.50 (s, 1H), 7.24 (s, 1H), 6.96 (brt, 1H), 4.95 (s, 2H), 3.52-3.44 (m, 4H), 3.26 (sept, 1H), 2.78 (s, 6H), 2.74 (s, 6H), 2.60 (s, 3H), 1.27-1.22 (m, 9H), 1.17(t, 3H)
Step 3: 4-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-2-isopropylphenyl dihydrogen phosphate
The intermediate compound(Step 2)(3.95g, 6.99mmol) was dissolved in 1,4-dioxane(200㎖), 12N HCl(200㎖) was added. The reaction mixture was stirred at RT for 3h, and evaporated in vacuo. After concentrated by decompression, the residue was purified by reversed phase chromatography to afford the intermediate compound(2.53g, 5.59mmol) in a yield of 80%.
1H-NMR (400 MHz, D2O) δ 7.30 (s, 1H), 6.76 (s, 1H), 3.26 (q, 2H), 3.08 (sept, 1H), 2.46 (s, 3H), 1.08 (t, 3H), 1.00(d, 6H)
Example 7
Sodium 4-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-2-isopropylphenyl phosphate (I-7)
4-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-2-isopropylphenyl dihydrogen phosphate(177mg, 0.39mmol) was dissolved in H2O(3.91㎖), and 1N NaOH(0.78㎖, 0.78mmol) was added. The reaction mixture was stirred at RT for 30 min, and evaporated in vacuo. After concentrated by decompression, the residue was dissolved in H2O and was lyophilized to afford the title compound(196㎎, 0.39mmol) in a yield of 99%.
1H-NMR (400 MHz, D2O) δ 7.27 (s, 1H), 6.87 (s, 1H), 3.27 (q, 2H), 3.14 (sept, 1H), 2.47 (s, 3H), 1.07 (t, 3H), 1.01(d, 6H)
Example 8
Potassium 4-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-6-isopropyl-1,3-phenylene diphosphate (I-8)
4-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl dihydrogen phosphate(1.00g, 1.87mmol) was dissolved in H2O(70㎖), and 1N KOH(36.59㎖, 36.59mmol) was added. The reaction mixture was stirred at RT for 30 min, and evaporated in vacuo. It was concentrated to afford the title compound(1.11g, 1.63mmol) in a yield of 87%.
1H-NMR (400 MHz, D2O) δ 7.40 (s, 1H), 7.33 (s, 1H), 3.46 (q, 2H), 3.38 (m, 1H), 2.63 (s, 3H), 1.26 (t, 3H), 1.16 (d, 6H)
Example 9
Potassium 2-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl phosphate (I-5)
2-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl dihydrogen phosphate(60mg, 0.13mmol) was dissolved in H2O(4.8㎖), and 1N KOH(0.26㎖, 0.26mmol) was added. After concentrated by decompression, the reaction mixture was stirred at RT for 30 min, and evaporated in vacuo to afford the title compound was freeze dried in vacuo to afford the title compound(64㎎, 0.12mmol) in a yield of 94%.
1H-NMR (400 MHz, D2O) δ 7.22 (s, 1H), 6.96 (s, 1H), 3.33 (q, 2H), 3.06 (sept, 1H), 2.49 (s, 3H), 1.12 (t, 3H), 1.02 (d, 6H)
Example 10
Potassium 4-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-2-isopropylphenyl phosphate (I-10)
4-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-2-isopropylphenyl dihydrogen phosphate(150㎎, 0.33mmol) was dissolved in H2O(3.31㎖), and 1N KOH(0.66㎖, 0.66mmol) was added. The reaction mixture was stirred at RT for 30 min, and evaporated in vacuo. After concentrated by decompression, the solvent was removed. The residue was dissolved in H2O and was freeze dried to afford the title compound (162㎎, 0.30mmol) in a yield of 93%.
1H-NMR (400 MHz, D2O) δ 7.27 (s, 1H), 6.87 (s, 1H), 3.27 (q, 2H), 3.14 (sept, 1H), 2.47 (s, 3H), 1.07 (t, 3H), 1.01(d, 6H)
Example 11
Calcium 4-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-6-isopropyl-1,3-phenylene diphosphate (I-11)
4-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl dihydrogen phosphate(1.00g, 1.87mmol) was dissolved in H2O(70㎖) and 1N Ca(OH)2(3.73㎖, 3.73mmol) was added. The reaction mixture was stirred at RT for 30 min, and evaporated in vacuo. The reaction mixture was concentrated by decompression to afford the title compound(1.01g, 1.66mmol) in a yield of 89%.
1H-NMR (400 MHz, D2O) δ 7.40 (s, 1H), 7.33 (s, 1H), 3.46 (q, 2H), 3.38 (m, 1H), 2.63 (s, 3H), 1.26 (t, 3H), 1.16 (d, 6H)
Example 12
Calcium 2-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl phosphate (I-12)
2-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl dihydrogen phosphate(60mg, 0.13mmol) was dissolved in H2O(4.8㎖), and 1N Ca(OH)2(0.13㎖, 0.13mmol) was added. The reaction mixture was stirred at RT for 30 min, and evaporated in vacuo. After concentrated by decompression, the solvent was removed to afford the title compound(52㎎, 0.11mmol) in a yield of 82%.
1H-NMR (400 MHz, D2O) δ 7.22 (s, 1H), 6.96 (s, 1H), 3.33 (q, 2H), 3.06 (sept, 1H), 2.49 (s, 3H), 1.12 (t, 3H), 1.02 (d, 6H)
Example 13
Calcium 4-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-2-isopropylphenyl phosphate (I-13)
4-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-2-isopropylphenyl dihydrogen phosphate(100㎎, 0.22mmol) was dissolved in H2O(2.2㎖). 1N Ca(OH)2(0.22㎖, 0.22mmol) was added. The reaction mixture was stirred at RT for 30 min, and evaporated in vacuo. After concentrated by decompression, the solvent was removed. The residue was dissolved in H2O and was free dried to afford the title compound(96㎎, 0.19mmol) in a yield of 89%.
1H-NMR (400 MHz, D2O) δ 7.27 (s, 1H), 6.87 (s, 1H), 3.27 (q, 2H), 3.14 (sept, 1H), 2.47 (s, 3H), 1.07 (t, 3H), 1.01(d, 6H)
Example 14
Magnesium 4-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-6-isopropyl-1,3-phenylene diphosphate (I-14)
4-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl dihydrogen phosphate(100㎎, 0.187mmol) was dissolved in H2O(7㎖). 1N Mg(OH)2(0.37㎖, 0.37mmol) was added. The reaction mixture was stirred at RT for 30 min, and evaporated in vacuo. It was concentrated by decompression to afford the title compound(79.8㎎, 0.14mmol) in a yield of 74%.
1H-NMR (400 MHz, D2O) δ 7.40 (s, 1H), 7.33 (s, 1H), 3.46 (q, 2H), 3.38 (m, 1H), 2.63 (s, 3H), 1.26 (t, 3H), 1.16 (d, 6H)
Example 15
Magnesium 2-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl phosphate (I-15)
2-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl dihydrogen phosphate(40㎎, 0.087mmol) was dissolved in H2O(3.2㎖). 1N Mg(OH)2(0.087㎖, 0.087mmol) was added. The reaction mixture was stirred at RT for 30 min, and evaporated in vacuo. After concentrated by decompression, the solvent was removed to afford the title compound(28.5㎎, 0.06mmol) in a yield of 82%.
1H-NMR (400 MHz, D2O) δ 7.22 (s, 1H), 6.96 (s, 1H), 3.33 (q, 2H), 3.06 (sept, 1H), 2.49 (s, 3H), 1.12 (t, 3H), 1.02 (d, 6H)
Example 16
Magnesium 4-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-2-isopropylphenyl phosphate (I-16)
4-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-2-isopropylphenyl dihydrogen phosphate(62㎎, 0.14mmol) was dissolved in H2O(1.36㎖), and 1N Mg(OH)2(0.14㎖, 0.14mmol) was added. The reaction mixture was stirred at RT for 30 min, and evaporated in vacuo. After concentrated by decompression, the solvent was removed. The residue was dissolved in H2O and was freeze dried to afford the title compound (42㎎, 0.11mmol) in a yield of 81%.
1H-NMR (400 MHz, D2O) δ 7.27 (s, 1H), 6.87 (s, 1H), 3.27 (q, 2H), 3.14 (sept, 1H), 2.47 (s, 3H), 1.07 (t, 3H), 1.01(d, 6H)
<EXPERIMENT 1> Solubility test
The solubility of the compound of Formula Ⅰ was examined to identify whether or not its solubility was superior to the compound of Formula Ⅱ(parent compound). The results are given as shown in Table 1.
The compound of Formula Ⅰ and the compound of Formula Ⅱ(parent compound) were dissolved respectively in deionized water. The solution was vigorously stirred for 30 seconds at 20±5℃ every 5 minutes and the solubility tests were performed within 30 minutes.
As shown in table 1, more than 10,000㎖ of water was required to dissolve the compound of Formula Ⅱ(parent compound). According to The Korean Pharmacopoeia, the compound of Formula Ⅱ can be a practically insoluble compound. The present invention relates to the compound of Formula Ⅰ which shows significant improvement in solubility because the solubility of the compound of Formula I was 1,000 to 20,000 times higher than that of the compound of Formula Ⅱ(parent compound).
Therefore, modified physicochemical characteristics of the compound of Formula Ⅰ may have positive effects on both developing formulations for a drug candidate and increasing bioavailability, due to its enhanced solubility.
<EXPERIMENT 2> Mouse Pharmacokinetics
Pharmacokinetic studies were performed to determine whether the compound of Formula Ⅰcould be converted to the compound of Formula Ⅱ(parent compound) in vivo and efficacious plasma concentration of the compound of Formula Ⅱ(parent compound) could be obtained by administrating the compound of Formula Ⅰ. Oral single dose(10㎖/㎏) of the compound of Formula Ⅰ was administered to male BALB/C mice. Blood was collected in tubes coated with lithium heparin at 10, 20, 30, 60, and 120 minutes. After centrifugation, plasma was harvested and kept frozen at -20℃.
Liquid-liquid extraction with ethyl acetate was used for plasma sample preparation. LC-MS/MS analysis was conducted to analyze the compound of Formula Ⅰ and Formula Ⅱ(parent compound). Pharmacokinetic parameters were determined by noncompartmental analysis(WinNonLin®), and PK results are given as shown in Table 2.
As shown in table 2, AUC0-120min (Area under the plasma concentration-time curve) and Cmax of the compound of Formula Ⅱ(parent compound) were 33,529 ng·min·㎖ -1 and 420 ng/㎖, respectively. AUC0-120min of the compound of Formula Ⅰ was 3 to 5 times higher than that of the compound of Formula Ⅱ as compared to its parent compound on a molecular weight and doses. Furthermore, the compound of Formula Ⅰ was absorbed more rapidly than its parent compound because Cmax of the compound of Formula Ⅰ was 10 to 20 times higher than that of the compound of Formula Ⅱ(parent compound) as compared to its parent drug on a molecular weight and doses.
Therefore, the present invention relates to the compound of Formula Ⅰ which displays much more improved PK profile than the compound of Formula Ⅱ( parent compound).
<EXPERIMENT 3> In vivo anticancer activity of compound
To determine the in vivo antitumor efficacy, the compound of Formula I was performed as follows.
A2780 Human ovarian cancer cells were established as subcutaneous xenografts by injection of 8×106 cells into the flanks of adult female Balb/c nude mice. Mice with established tumors (50-200 mm3) were selected for study (n=3~6/treatment group). The compound of Formula I (I-1, I-2, I-3, I-7) were formulated in deionized water and administered orally (po) at a dose of 200㎎/㎏. The vehicle alone was administered to control groups. Animals were dosed 5 days per week (Monday through Friday) for 2 consecutive weeks.
Animals were weighed and tumor size was determined twice weekly by digital caliper measurements, and tumor volumes were calculated(volume = [length×width2]/2(mm3), where length and width refer to the larger and smaller dimensions collected at each measurement). The mean tumor volumes of each group were calculated. The change in mean treated tumor volume was divided by the change in mean control tumor volume, multiplied by 100 and subtracted from 100% to give the tumor growth inhibition for each group. (Table 3)
Tumor growth inhibition (TGI) was calculated as follows:
TGI(%) = (1-DT/DC) x 100
wherein DT and DC represent the mean tumor volume changes in treatment and control groups, respectively.
As shown in table 3, the compound of Formula Ⅰ significantly inhibited tumor growth in vivo.
According to experiment 1, 2, and 3, the novel compound of Formula Ⅰexhibits more improved solubility by approximately 1,000 to 20,000 times compared to the compound of Formula Ⅱ(parent compound). Moreover, the compound of Formula Ⅰ has more favorable PK profile. As compared to its parent drug on a molecular weight and doses, AUC0-120min and Cmax of the compound of Formula Ⅰ were 3 to 5 times and 10 to 20 times higher than those of the compound of Formula Ⅱ, respectively. Therefore, the improved PK profile of the compound of Formula Ⅰ can be useful in developing a new anticancer drug candidate.
Claims (11)
- The compound of Formula I according to claim 1, wherein R1 and R2 are both PO(OH)2, or wherein R1 and R2 are differently selected from each other hydrogen or PO(OH)2.
- The compound of Formula I according to claim 1, which is selected from the group consisting of the following compounds:4-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-6-isopropyl-1,3-phenylene bis(dihydrogen phosphate),(S)-2-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl 2,6-diaminohexanoate dihydrochloride,Sodium 4-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-6-isopropyl-1,3-phenylene diphosphate,2-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl dihydrogen phosphate,Sodium 2-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl phosphate,4-(3-(Ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-2-isopropylphenyl dihydrogen phosphate,Sodium 4-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-2-isopropylphenyl phosphate,Potassium 4-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-6-isopropyl-1,3-phenylene diphosphate,Potassium 2-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl phosphate,Potassium 4-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-2-isopropylphenyl phosphate,Calcium 4-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-6-isopropyl-1,3-phenylene diphosphate,Calcium 2-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl phosphate,Calcium 4-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-2-isopropylphenyl phosphate,Magnesium 4-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-6-isopropyl-1,3-phenylene diphosphate,Magnesium 2-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-4-isopropylphenyl phosphate, orMagnesium 4-(3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazol-5-yl)-5-hydroxy-2-isopropylphenyl phosphate.
- A pharmaceutical composition for use in the treatment of tumor, comprising pharmaceutically acceptable excipient and a compound of Formula I in any one of claims 1-5.
- The use of a compound of Formula I in any one of claims 1-5 for the treatment of tumor.
- A process for preparing a compound of Formula I as defined in claim 2, which process comprises deprotection of the obtained intermediate compound with HCl after synthesizing it with boc(tert-butoxy carbonyl) protected lysine by esterification the compound of Formula II as below with Boc-Lys(Boc)-OH in methylene chloride solvent.<Formula Ⅱ>
- A process for preparing a compound of Formula I as defined in claim 3, which process comprises hydrolyzing the obtained bis(tetramethylphosphorodiamidate) intermediate compound with trifluoroacetic acid or HCl after synthesizing it by substitution reaction of the compound of Formula II as below with tetramethylphosphorodiamidic chloride in H2O or dioxane solvent<Formula Ⅱ>
- A process for preparing a compound of Formula I as defined in claim 4, which process comprises base reaction of compound of Formula Ib as below with an inorganic base selected from NaOH, KOH, Ca(OH)2 or Mg(OH)2<Formula Ib>,wherein R1 and R2 are both PO(OH)2 ,or wherein R1 and R2 are differently selected from each other hydrogen or PO(OH)2 .
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20110074867 | 2011-07-28 | ||
KR10-2011-0074867 | 2011-07-28 | ||
KR1020120082521A KR20130018548A (en) | 2011-07-28 | 2012-07-27 | Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide |
KR10-2012-0082521 | 2012-07-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013015661A2 true WO2013015661A2 (en) | 2013-01-31 |
WO2013015661A3 WO2013015661A3 (en) | 2013-05-02 |
Family
ID=47601688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2012/006043 WO2013015661A2 (en) | 2011-07-28 | 2012-07-27 | Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2013015661A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9533002B2 (en) | 2012-05-25 | 2017-01-03 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-β |
US10023864B2 (en) | 2014-06-06 | 2018-07-17 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta |
WO2019059344A1 (en) | 2017-09-22 | 2019-03-28 | 大日本住友製薬株式会社 | Chemically activated water-soluble prodrug |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004072051A1 (en) * | 2003-02-11 | 2004-08-26 | Vernalis (Cambridge) Limited | Isoxazole compounds as inhibitors of heat shock proteins |
WO2008104595A1 (en) * | 2007-03-01 | 2008-09-04 | Novartis Ag | Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms |
WO2009036012A1 (en) * | 2007-09-10 | 2009-03-19 | Curis, Inc. | Hsp90 inhibitors containing a zinc binding moiety |
WO2011102660A2 (en) * | 2010-02-17 | 2011-08-25 | Ildong Pharm Co., Ltd. | A novel 5-membered heterocycle derivatives and manufacturing process thereof |
-
2012
- 2012-07-27 WO PCT/KR2012/006043 patent/WO2013015661A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004072051A1 (en) * | 2003-02-11 | 2004-08-26 | Vernalis (Cambridge) Limited | Isoxazole compounds as inhibitors of heat shock proteins |
WO2008104595A1 (en) * | 2007-03-01 | 2008-09-04 | Novartis Ag | Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms |
WO2009036012A1 (en) * | 2007-09-10 | 2009-03-19 | Curis, Inc. | Hsp90 inhibitors containing a zinc binding moiety |
WO2011102660A2 (en) * | 2010-02-17 | 2011-08-25 | Ildong Pharm Co., Ltd. | A novel 5-membered heterocycle derivatives and manufacturing process thereof |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9533002B2 (en) | 2012-05-25 | 2017-01-03 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-β |
US10023864B2 (en) | 2014-06-06 | 2018-07-17 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta |
WO2019059344A1 (en) | 2017-09-22 | 2019-03-28 | 大日本住友製薬株式会社 | Chemically activated water-soluble prodrug |
Also Published As
Publication number | Publication date |
---|---|
WO2013015661A3 (en) | 2013-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018182341A1 (en) | Pyrrolobenzodiazepine dimer precursor and ligand-linker conjugate compound thereof | |
WO2014107024A1 (en) | Antibody-linker-drug conjugate, preparation method therefor, and anticancer drug composition containing same | |
WO2021040356A1 (en) | C-nucleosides, c-nucleotides and their analogs, equivalents and prodrugs thereof for ectonucleotidase inhibition | |
WO2018155947A1 (en) | Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer | |
WO2021137646A1 (en) | Pyrrolobenzodiazepine derivative and ligand-linker conjugate thereof | |
WO2015160192A1 (en) | Pharmaceutical composition for treating and preventing leukemia, containing thienopyrimidine derivative or pharmaceutically acceptable salt thereof | |
WO2020149553A1 (en) | Aryl or heteroaryl derivative, and pharmaceutical composition comprising same as active ingredient for treatment of kinase-related disease | |
WO2020106119A1 (en) | Pharmaceutical composition comprising histone deacetylase 6 inhibitors | |
WO2018199633A1 (en) | Pharmaceutical composition for preventing or treating aging-related diseases containing decursin derivative as active ingredient | |
WO2013015661A2 (en) | Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide | |
WO2021086069A1 (en) | Compound comprising ezh2 inhibitor and e3 ligase binder and pharmaceutical composition for preventing or treating ezh2-associated disease comprising same as active ingredient | |
WO2020222541A1 (en) | Prodrug of caspase inhibitor | |
WO2011105643A1 (en) | Selenalzole derivative having ligand which activates peroxisome proliferator activated receptor (ppar), preparing method thereof and usage of the chemical compounds | |
WO2022177313A1 (en) | Sesquiterpene derivative or pharmaceutically acceptable salt thereof and use thereof | |
WO2021149900A1 (en) | Disubstituted adamantyl derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition for suppressing cancer growth comprising same as active ingredient | |
WO2011102660A2 (en) | A novel 5-membered heterocycle derivatives and manufacturing process thereof | |
WO2022149925A1 (en) | Novel tryptophan hydroxylase inhibitor and use thereof | |
EP3386988A1 (en) | Novel dihydropyranopyrimidinone derivatives, and use thereof | |
WO2015002434A1 (en) | Novel tenofovir disoproxil salt and the preparation method thereof | |
WO2020040326A1 (en) | Phenylacetic acid derivative, and composition for preventing or treating autoimmune diseases, containing same as active ingredient | |
WO2022177307A1 (en) | Interferon gene stimulator composition comprising benzimidazole derivative as active ingredient | |
WO2024005485A1 (en) | Saponin derivative compound, and pharmaceutical composition for preventing or treating coronavirus infection comprising same | |
WO2024128335A1 (en) | Pharmaceutical composition for preventing or treating bone diseases | |
WO2021091358A1 (en) | Prostaglandin analogs and uses thereof | |
WO2024071959A1 (en) | Method for preparing choline alposcerate ester derivative and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12816959 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12816959 Country of ref document: EP Kind code of ref document: A2 |